Non-steroidal Mineralocorticoid Receptor Antagonist Eliciting Cardiorenal Protection is a New Option for Patients with Chronic Kidney Disease
Background: Mineralocorticoid receptor antagonists (MRAs) protect cardiorenal function by robust anti-inflammatory and antifibrotic functions beyond classical functions of maintaining fluid and electrolyte homeostasis. The application of traditional steroidal MRAs to chronic kidney disease (CKD) ha...
Main Authors: | Wenyu Liu, Shengqiang Yu |
---|---|
Format: | Article |
Language: | English |
Published: |
Karger Publishers
2022-11-01
|
Series: | Kidney Diseases |
Online Access: | https://www.karger.com/Article/FullText/528066 |
Similar Items
-
Nonsteroidal Mineralocorticoid Receptor Antagonist (Finerenone) in Cardiorenal Disease
by: Monarch Shah, et al.
Published: (2023-09-01) -
Mineralocorticoid Receptor Antagonists—Use in Chronic Kidney Disease
by: Wiktoria Baran, et al.
Published: (2021-09-01) -
Potential Impact of Non-Steroidal Mineralocorticoid Receptor Antagonists in Cardiovascular Disease
by: Asadur Rahman, et al.
Published: (2023-01-01) -
Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease
by: Nina Vodošek Hojs, et al.
Published: (2021-06-01) -
Renal Protection of Mineralocorticoid Receptor Antagonist, Finerenone, in Diabetic Kidney Disease
by: Dong-Lim Kim, et al.
Published: (2023-02-01)